FindTrial
Sign In

Comprehensive analysis of rebleeding after endoscopic treatment for secondary prophylaxis of esophagogastric variceal in cirrhotic patients

Comprehensive analysis of rebleeding after endoscopic treatment for secondary prophylaxis of esophagogastric variceal in cirrhotic patients - Rebleeding after secondary prophylaxis for esophagogastric variceal

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300067912
Enrollment
Unknown
Registered
2023-01-31
Start date
2023-02-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver cirrhosis and gastroesophageal varices

Interventions

rebleeding group and non-rebleeding group:No

Sponsors

The 960th Hospital of the PLA
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. The diagnosis of liver cirrhosis is evaluated according to the diagnostic criteria in liver cirrhosis diagnosis and treatment guidelines. 2. The diagnosis of gastroesophageal varices was based on endoscopic fndings when the bleeding was stabilized. Endoscopic fndings of esophageal varices were evaluated according to the grading system.

Exclusion criteria

Exclusion criteria: 1. Age less than 18 years; 2. Patients with liver cancer or other malignant tumors; 3. Patients with severe diseases of vital organs such as heart, lung, kidney, brain and blood affect their survival; 4. Lost to follow up and incomplete data.lutw

Design outcomes

Primary

MeasureTime frame
time interval for rebleeding;—

Countries

China

Contacts

Public ContactXiaofeng Liu

The 960th Hospital of the PLA

liuxf0531@163.com+86 531 51665320

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026